141 related articles for article (PubMed ID: 11021604)
1. Declining ovarian cancer rates in U.S. women in relation to parity and oral contraceptive use.
Gnagy S; Ming EE; Devesa SS; Hartge P; Whittemore AS
Epidemiology; 2000 Mar; 11(2):102-5. PubMed ID: 11021604
[TBL] [Abstract][Full Text] [Related]
2. The effects of oral contraceptives and parity on ovarian cancer trends in women under 55 years of age.
Villard-Mackintosh L; Vessey MP; Jones L
Br J Obstet Gynaecol; 1989 Jul; 96(7):783-8. PubMed ID: 2788456
[TBL] [Abstract][Full Text] [Related]
3. Parity and Oral Contraceptive Use in Relation to Ovarian Cancer Risk in Older Women.
McGuire V; Hartge P; Liao LM; Sinha R; Bernstein L; Canchola AJ; Anderson GL; Stefanick ML; Whittemore AS
Cancer Epidemiol Biomarkers Prev; 2016 Jul; 25(7):1059-63. PubMed ID: 27197274
[TBL] [Abstract][Full Text] [Related]
4. Worldwide variations in the lifetime probability of reproductive cancer in women: implications of best-case, worst-case, and likely-case assumptions about the effect of oral contraceptive use.
Petitti DB; Porterfield D
Contraception; 1992 Feb; 45(2):93-104. PubMed ID: 1559340
[TBL] [Abstract][Full Text] [Related]
5. Recent trends in incidence of and mortality from breast, ovarian and endometrial cancers in England and Wales and their relation to changing fertility and oral contraceptive use.
dos Santos Silva I; Swerdlow AJ
Br J Cancer; 1995 Aug; 72(2):485-92. PubMed ID: 7640237
[TBL] [Abstract][Full Text] [Related]
6. Personal and environmental characteristics related to epithelial ovarian cancer. I. Reproductive and menstrual events and oral contraceptive use.
Wu ML; Whittemore AS; Paffenbarger RS; Sarles DL; Kampert JB; Grosser S; Jung DL; Ballon S; Hendrickson M; Mohle-Boetani J
Am J Epidemiol; 1988 Dec; 128(6):1216-27. PubMed ID: 3195563
[TBL] [Abstract][Full Text] [Related]
7. Ovarian cancer incidence (1989-1991) and mortality (1954-1993) in The Netherlands.
Koper NP; Kiemeney LA; Massuger LF; Thomas CM; Schijf CP; Verbeek AL
Obstet Gynecol; 1996 Sep; 88(3):387-93. PubMed ID: 8752245
[TBL] [Abstract][Full Text] [Related]
8. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation.
Modan B; Hartge P; Hirsh-Yechezkel G; Chetrit A; Lubin F; Beller U; Ben-Baruch G; Fishman A; Menczer J; Struewing JP; Tucker MA; Wacholder S;
N Engl J Med; 2001 Jul; 345(4):235-40. PubMed ID: 11474660
[TBL] [Abstract][Full Text] [Related]
9. Personal characteristics relating to risk of invasive epithelial ovarian cancer in older women in the United States.
Whittemore AS
Cancer; 1993 Jan; 71(2 Suppl):558-65. PubMed ID: 8420677
[TBL] [Abstract][Full Text] [Related]
10. The reduction in risk of ovarian cancer associated with oral-contraceptive use.
Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development
N Engl J Med; 1987 Mar; 316(11):650-5. PubMed ID: 3821795
[TBL] [Abstract][Full Text] [Related]
11. Ovarian and endometrial cancers.
Mant JW; Vessey MP
Cancer Surv; 1994; 19-20():287-307. PubMed ID: 7895220
[TBL] [Abstract][Full Text] [Related]
12. Oral contraceptives and neoplasia of the ovary.
Stanford JL
Contraception; 1991 Jun; 43(6):543-56. PubMed ID: 1868732
[TBL] [Abstract][Full Text] [Related]
13. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 U.S. case-control studies. VI. Nonepithelial cancers among adults. Collaborative Ovarian Cancer Group.
Horn-Ross PL; Whittemore AS; Harris R; Itnyre J
Epidemiology; 1992 Nov; 3(6):490-5. PubMed ID: 1329996
[TBL] [Abstract][Full Text] [Related]
14. A case-control study of oral contraceptive use and invasive epithelial ovarian cancer.
Rosenberg L; Palmer JR; Zauber AG; Warshauer ME; Lewis JL; Strom BL; Harlap S; Shapiro S
Am J Epidemiol; 1994 Apr; 139(7):654-61. PubMed ID: 8166126
[TBL] [Abstract][Full Text] [Related]
15. Pooled analysis of 3 European case-control studies of epithelial ovarian cancer: III. Oral contraceptive use.
Franceschi S; Parazzini F; Negri E; Booth M; La Vecchia C; Beral V; Tzonou A; Trichopoulos D
Int J Cancer; 1991 Aug; 49(1):61-5. PubMed ID: 1874572
[TBL] [Abstract][Full Text] [Related]
16. Factors affecting the association of oral contraceptives and ovarian cancer.
Cramer DW; Hutchison GB; Welch WR; Scully RE; Knapp RC
N Engl J Med; 1982 Oct; 307(17):1047-51. PubMed ID: 7121514
[TBL] [Abstract][Full Text] [Related]
17. Why have ovarian cancer mortality rates declined? Part I. Incidence.
Sopik V; Iqbal J; Rosen B; Narod SA
Gynecol Oncol; 2015 Sep; 138(3):741-9. PubMed ID: 26080287
[TBL] [Abstract][Full Text] [Related]
18. Characteristics relating to ovarian cancer risk: collaborative analysis of seven U.S. case-control studies. Epithelial ovarian cancer in black women. Collaborative Ovarian Cancer Group.
John EM; Whittemore AS; Harris R; Itnyre J
J Natl Cancer Inst; 1993 Jan; 85(2):142-7. PubMed ID: 8418303
[TBL] [Abstract][Full Text] [Related]
19. Epithelial ovarian cancer and combination oral contraceptives.
Rosenberg L; Shapiro S; Slone D; Kaufman DW; Helmrich SP; Miettinen OS; Stolley PD; Rosenshein NB; Schottenfeld D; Engle RL
JAMA; 1982 Jun; 247(23):3210-2. PubMed ID: 7045417
[TBL] [Abstract][Full Text] [Related]
20. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls.
; Beral V; Doll R; Hermon C; Peto R; Reeves G
Lancet; 2008 Jan; 371(9609):303-14. PubMed ID: 18294997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
